Celsion Corporation has done a 61.8 percent Fibonacci retracement after exploding 180 percent higher last week after releasing data from its Ovation Study.
The Ovation Study is a Phase Ib dose escalating clinical trial combining GEN-1, the company's DNA-based immunotherapy, with the standard of care for the treatment of newly-diagnosed patients with advanced Stage III/IV ovarian cancer who will undergo neoadjuvant chemotherapy followed by interval debulking surgery.
Author: Lance Jepsen
For ethical purposes, I try not to hold any position in any stock I profile on GuerillaStockTrading.com unless specifically stated in the article. Owner of GuerillaStockTrading.com. Seasoned entrepreneur, investor, and writer. I love God, family, country, stock trading, economics, and helping people learn how to trade. View all posts by Lance Jepsen